Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man

  • C. Anthony Hunt
  • Reese T. Jones
  • Ronald I. Herning
  • John Bachman


The pharmacokinetics of Δ9-tetrahydrocannabinol (THC) administered intravenously was evaluated in four subjects after oral administration of placebo and 1500 mg of cannabidiol (CBD) according to a crossover design. The cannabidiol pretreatment had no apparent effect on THC pharmacokinetics, yet there may have been minimal effect on the formation and excretion of metabolites. The total (metabolic) blood clearance of THC averaged 17.4 ml/min/kg without CBD and 20.9 ml/min/kg with CBD, and was probably hepatic blood flow limited. The apparent steady-state volume of distribution averaged 9.86 (with CBD, 10.54) liters/kg. Irrespective of CBD pretreatment, the renal clearance of THC metabolites ranged from 17 ml/min after approximately 1 hr to 1.13 ml/min 3.5days after dosing with THC. The apparent terminal half life for metabolites averaged 8.2 days.

Key words

cannabidiol tetrahydrocannabinol pharmacokinetics cannabinoids pharmacodynamics metabolism renal clearance protein binding 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Mechoulam, A. Shani, E. Edery, and Y. Greenfield. Chemical basis of hashish activity.Science 169:611–612 (1970).PubMedCrossRefGoogle Scholar
  2. 2.
    M. Perez-Reyes, M. C. Timmons, K. H. Davis, and E. M. Wall. A comparison of the pharmacological activity in man of intravenously administered Δ9-tetrahydrocannabinol, cannabinol and cannabidiol.Experientia 29:1368–1369 (1973).PubMedCrossRefGoogle Scholar
  3. 3.
    S. A. Turkanis, W. Caley, D. M. Olsen, and R. Karler. Anticonvulsant properties of cannabidiol.Res. Commun. Chem. Pathol Pharmacol. 8:231–246 (1974).PubMedGoogle Scholar
  4. 4.
    W. S. Dalton, R. Martz, L. Lemberger, B. E. Rodda, and R. B. Forney. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects.Clin. Pharmacol. Ther,19:300–309 (1976).PubMedGoogle Scholar
  5. 5.
    W. D. M. Paton and R. G. Pertwee. Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism.Br. J. Pharmacol. 44:250–261 (1972).PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    A. J. Siemans, H. Kalant, and J. C. deNie. Metabolic interactions between delta-9-tetrahydrocannabinol and other cannabinoids in rats. In M. C. Braude and S. Szara (eds.),The Pharmacology of Marihuana, Raven Press, New York, 1976, pp. 77–92.Google Scholar
  7. 7.
    B. B. Caldwell, K. Bailey, C. J. Paul, and G. Anderson. Interaction of cannabinoids with pentobarbital in rats.Toxicol. Appl. Pharmacol. 29:59–69 (1974).CrossRefGoogle Scholar
  8. 8.
    G. Jones and R. G. Pertwee. A metabolic interactionin vivo between cannabi'nol and delta-1-tetrahydrocannabinol.Br. J. Pharmacol. 45: 375–377 (1972).PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    A. J. Siemens, H. Kalant, J. M. Khanna, J. Marshman, and G. Ho. Effect of cannabis on pentobarbital-induced sleeping time and pentobarbital metabolism in the rat.Biochem. Pharmacol. 23:477–488 (1974).PubMedCrossRefGoogle Scholar
  10. 10.
    N. L. Benowitz, T. L. Nguyen, R. T. Jones, R. I. Herning, and J. Bachman. Metabolic and psychophysiologic studies of cannabidiol-hexobarbitai interaction.Clin. Pharmacol. Ther. 28:115–120(1980).PubMedCrossRefGoogle Scholar
  11. 11.
    W. S. Dalton, R. Martz, B. E. Rodda, L. Lemberger, and R. B. Forney. Influence of cannabidiol on secobarbital effects and plasma kinetics.Clin. Pharmacol. Ther. 30:695–700 (1976).Google Scholar
  12. 12.
    B. E. Belgrave, K. D. Bird, and G. B. Chesher. The effect of cannabidiol, alone and in combination with ethanol, on human performance.Psychopharmacology 64:243–246 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    L. E. Hollister and H. Gillespie. Interactions in man of Δ9-tetrahydrocannabinol. I. Cannabinol and cannabidiol.Clin. Pharmacol. Ther. 18:80–93 (1975).PubMedGoogle Scholar
  14. 14.
    I. G. Karniol, I. Shirakawa, N. Kasinski, A. Pfeferman, and I. G. Carlini. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man.Eur. J. Pharmacol. 28:172–177 (1974).PubMedCrossRefGoogle Scholar
  15. 15.
    C. A. Hunt and R. T. Jones. Tolerance and disposition of tetrahydrocannabinoi in man.J. Pharmacol. Exp. Ther. 215:35–44 (1981).Google Scholar
  16. 16.
    R. T. Jones, N. Benowitz, and J. Bachman. Clinical studies of cannabis tolerance and dependence.Ann. N. Y. Acad. Sci. 282:221–239 (1976).PubMedCrossRefGoogle Scholar
  17. 17.
    E. R. Garrett and C. A. Hunt. Separation and analysis of Δ9-tetrahydrocannabinol in biological fluids by high-pressure liquid chromatography and GLC.J. Pharm. Sci. 66:20–26 (1977).PubMedCrossRefGoogle Scholar
  18. 18.
    E. R. Garrett, A. J. Gouyette, and C. A. Hunt. GLC and HPLC analysis of cannabinoids in biological fluids and applications. In J. A. Vinson (ed.),Cannabinoid Analysis in Physiological Fluids, ACS Symposium Series 98, Am. Chem. Soc., Washington, D.C., 1979, pp. 13–37.CrossRefGoogle Scholar
  19. 19.
    L. Lemberger, N. R. Tamarkin, J. Axelrod, and I. J. Kopin. Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marijuana users.Science 173:72–74 (1971).PubMedCrossRefGoogle Scholar
  20. 20.
    L. Z. Benet. General treatment of linear mammallary models with elimination from any compartment as used in pharmacokinetics.J. Pharm. Sci. 61:536–541 (1972).PubMedCrossRefGoogle Scholar
  21. 21.
    E. R. Garrett and C. A. Hunt. Pharmacokinetics of delta-9-tetrahydrocannabinol in dogs.J. Pharm. Sci. 66:395–407 (1977).PubMedCrossRefGoogle Scholar
  22. 22.
    C. M. Metzler.A User's Manual for NONLIN, The Upjohn Co., Technical Report 7292/69/7292/005, 1969, Kalamazoo, Mich.Google Scholar
  23. 23.
    D. S. Riggs.The Mathematical Approach to Physiological Problems, 2nd edn. M.I.T. Press, Cambridge, Mass., 1972, pp. 146–161.Google Scholar
  24. 24.
    J. G. Wagner. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from coefficients and exponents of polyexponential equations which have been fitted to the data.J. Pharmacokin. Biopharm. 4:443–467 (1976).CrossRefGoogle Scholar
  25. 25.
    M. Wahlquist, I. M. Nilsson, F. Sandberg, S. Agurell, and B. Granstrand. Binding of delta-1-tetrahydrocannabinol to human plasma proteins.Biochem. Pharmacol. 19:2579–2584 (1970).CrossRefGoogle Scholar
  26. 26.
    E. R. Garrett and C. A. Hunt. Physicochemical properties, solubility and protein binding of delta-9-tetrahydrocannabinol.J. Pharm. Sci. 63:1056–1064 (1974).PubMedCrossRefGoogle Scholar
  27. 27.
    N. K. McCallum and M. E. Eastwood.In vivo binding of delta-1-tetrahydrocannabinol and cannabinol to rat serum proteins.J. Pharm. Pharmacol. 30:384–386 (1978).PubMedCrossRefGoogle Scholar
  28. 28.
    K. O. Fehr and H. Kalant. Fate of14C-delta-1-THC in rat plasma after intravenous injection and smoking.Eur. J. Pharmacol. 25:1–8 (1974).PubMedCrossRefGoogle Scholar
  29. 29.
    F. C. Law. Metabolism and disposition of Δ1 -tetrahydrocannabinol by the isolated perfused rabbit lung.Drug Metab. Dispos. 6:154–163 (1978).PubMedGoogle Scholar
  30. 30.
    G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance.Clin. Pharmacol. Ther. 18:377–379 (1975).PubMedGoogle Scholar
  31. 31.
    H. K. Borys, G. B. Ingall, and R. Karler. Development of tolerance to the prolongation of hexobarbitone sleeping time caused by cannabidiol.Br. J. Pharmacol. 67:93–101 (1979).PubMedCentralPubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1981

Authors and Affiliations

  • C. Anthony Hunt
    • 1
  • Reese T. Jones
    • 2
    • 3
  • Ronald I. Herning
    • 2
  • John Bachman
    • 2
  1. 1.School of PharmacyUniversity of CaliforniaSan Francisco
  2. 2.Langley Porter Psychiatric InstituteUniversity of CaliforniaSan Francisco
  3. 3.Recipient of National Institute on Drug Abuse Research Scientist Award DA-00053USA

Personalised recommendations